echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Patient model assists drug development and reproduces the heterogeneity of drug response in children with high-grade glioma in vitro 

    Nat Commun: Patient model assists drug development and reproduces the heterogeneity of drug response in children with high-grade glioma in vitro 

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Brain tumors are the main cause of childhood cancer-related morbidity and mortality


    Child diagnosis

    Existing genome-wide analysis studies have changed our understanding of pHGGs and clarified different molecular characteristics compared with adult HGG, including the close relationship between tumor location, patient age and recurrent mutations, indicating the pathogenesis and developmental background of pHGG There is a close connection between


    In 2016, the World Health Organization's Central Nervous System Tumor Classification (CNS) included molecular-based criteria and defined diffuse midline glioma-H3K27M mutant (DMG-K27M) as a unique diagnostic entity


    H3K27M mutations most commonly occur in 2 of the 15 genes encoding histone H3, of which H3F3A encodes H3.


    In vitro and in vivo disease models that reflect the close connection between the developmental background and pathogenesis of pHGG are essential to promote understanding and identify treatment loopholes


    The results showed that these models reproduced the histopathology, DNA methylation characteristics, mutations, and gene expression patterns of the patient's tumors from which they were derived , and included rare subgroups that are not well represented by existing models


    Reproduced the histopathology, DNA methylation characteristics, mutations and gene expression patterns of the patient tumors from which they were derived.


    The genomic profile of PDOX and cell lines retains matching changes that exist in the patient’s tumor and represents various pHGG subtypes


    The genomic profile of PDOX and cell lines retains matching changes that exist in the patient’s tumor and represents various pHGG subtypes


    Predicted different responses to PI3K/mTOR and MEK pathway inhibitors in vivo Predicted different responses to PI3K/mTOR and MEK pathway inhibitors in vivo

    These unique new models and online interactive data used to explore relevant detailed molecular characteristics and HTS chemosensitivity data provide a wealth of resources for pediatric brain tumor research


     

    Original source:

    Original source:

    Chen He et al.


    Chen He et al.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.